BioScrip Price Target Cut to $11.00 by Analysts at Jefferies Group (BIOS)
Equities researchers at Jefferies Group reduced their price target on shares of BioScrip (NASDAQ:BIOS) from $17.00 to $11.00 in a research report issued on Friday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target points to a potential upside of 24.43% from the company’s current price.
BioScrip (NASDAQ:BIOS) traded up 0.68% during mid-day trading on Friday, hitting $8.84. The stock had a trading volume of 1,737,298 shares. BioScrip has a 52-week low of $8.29 and a 52-week high of $17.62. The stock has a 50-day moving average of $11.79 and a 200-day moving average of $13.80. The company’s market cap is $599.2 million.
BioScrip (NASDAQ:BIOS) last announced its earnings results on Wednesday, August 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.09. The company had revenue of $190.73 million for the quarter, compared to the consensus estimate of $206.47 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was up 22.3% on a year-over-year basis. On average, analysts predict that BioScrip will post $0.20 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Noble Financial cut their price target on shares of BioScrip (NASDAQ:BIOS) from $16.00 to $13.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “hold” rating on shares of BioScrip (NASDAQ:BIOS) in a research note to investors on Wednesday. They now have a $15.00 price target on the stock. Finally, analysts at Dougherty & Co cut their price target on shares of BioScrip (NASDAQ:BIOS) from $15.00 to $10.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. BioScrip currently has an average rating of “Buy” and an average price target of $13.75.
BioScrip, Inc (NASDAQ:BIOS) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.